Recalls, Market Withdrawals, and Safety Alerts Important to GI – Archives
September 7, 2011
FDA notified healthcare professionals that the Boxed Warning for the entire class of Tumor Necrosis Factor-alpha (TNFα) blockers has been updated to include the risk of infection from two bacterial pathogens, Legionella and Listeria
The Food and Drug Administration (FDA) has determined that Halflytely and Bisacodyl Tablets Bowel Prep Kit (polyethylene glycol (PEG) 3350, sodium chloride, sodium bicarbonate, and potassium chloride for oral solution and two bisacodyl delayed release tablets, 5 milligrams (mg) (10-mg bisacodyl)) was withdrawn from sale for reasons of safety or effectiveness. The Agency will not accept or approve abbreviated new drug applications (ANDAs) for bowel prep kits containing PEG-3350, sodium chloride, sodium bicarbonate, and potassium chloride for oral solution and two bisacodyl delayed release tablets, 5 mg.
April 14, 2011
FDA reports of a rare cancer of white blood cells primarily in adolescents and young adults being treated for Crohn’s disease and ulcerative colitis with tumor necrosis factor (TNF) blockers
FDA notified healthcare professionals and the public that prescription proton pump inhibitor (PPI) drugs may cause low serum magnesium levels (hypomagnesemia) if taken for prolonged periods of time (in most cases, longer than one year). Healthcare professionals should consider obtaining serum magnesium levels prior to initiation of prescription PPI treatment in patients expected to be on these drugs for long periods of time, as well as patients who take PPIs with medications such as digoxin, diuretics or drugs that may cause hypomagnesemia.
FDA Drug Safety Communication: PPIs and Possible Fracture Risk
May 4, 2010
Recall: Baxter Colleague Pump
March 12, 2010
Plavix – Boxed Warning
Federal government issues joint-safety announcement re: Preventing Cross-Contamination in Endoscope Processing
November 17, 2009
FDA Recommendation on Plavix and PPIs